Lipoprotein (a) in patients on hemodialysis

Lipoprotein (a) [Lp(a)] may produce thrombogenic effects by modulating the fibrinolytic system. Elevated levels of Lp(a) have also been associated with an increased risk for atherosclerosis. Because atherosclerosis is more prevalent among patients with end-stage renal disease, the role of Lp(a) among patients on hemodialysis is analyzed. Twenty patients were studied. Lp(a) was measured before and after a hemodialysis session and before the following session. Between the first and second measures there was no statistical difference but when first and third measures were compared, a statistical difference (increase) was found. In conclusion, changes in Lp(a) levels were found and perhaps these changes are related to the episodic inflammation affecting patients on hemodialysis. The significance of these changes and the role in accelerating atherosclerosis in patients with end-stage renal disease are unknown.